Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Other Non-Current Liabilities (2024 - 2025)

Krystal Biotech's Other Non-Current Liabilities history spans 2 years, with the latest figure at $3.7 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 160.75% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $3.7 million, up 160.75%, while the annual FY2025 figure was $3.7 million, 160.75% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $3.7 million at Krystal Biotech, up from $3.1 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $3.7 million in Q4 2025 and bottomed at $588000.0 in Q2 2024.